Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mircea Dediu

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancerKimio Yonesaka, Kenji Hirotani, Joachim von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2008
The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational studyMircea Dediu, Emilia Crisan, Maria Radut, et al.
Current Oncology (Toronto, Ont.)|August 25, 2022
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)Urška Janžič, Nina Turnšek, Mircea Dediu, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|December 18, 2013
An international survey of practice patterns and difficulties in cancer pain management in Southeastern Europe: a Turkish & Balkan Oncology Group common initiativeAjlan Atasoy, Gordana Bogdanovic, Archil Aladashvili, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patientsMircea Dediu, Teodor Horvat, Alin Tarlea, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2024
Lung Cancer in RomaniaGheorghe-Emilian Olteanu, Alon Vigdorovits, Robert Alexandru Barna, et al.
BMC Proceedings|January 17, 2024
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityMaximilian J Hochmair, Mojca Unk, Jelena Spasic, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Clinical Lung Cancer|August 9, 2014
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerJean-Louis Pujol, Luis Paz-Ares, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE TrialMartin Reck, Mark A Socinski, Alexander Luft, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancerKimio Yonesaka, Kenji Hirotani, Joachim von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2008
The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational studyMircea Dediu, Emilia Crisan, Maria Radut, et al.
Current Oncology (Toronto, Ont.)|August 25, 2022
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)Urška Janžič, Nina Turnšek, Mircea Dediu, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|December 18, 2013
An international survey of practice patterns and difficulties in cancer pain management in Southeastern Europe: a Turkish & Balkan Oncology Group common initiativeAjlan Atasoy, Gordana Bogdanovic, Archil Aladashvili, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patientsMircea Dediu, Teodor Horvat, Alin Tarlea, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 7, 2024
Lung Cancer in RomaniaGheorghe-Emilian Olteanu, Alon Vigdorovits, Robert Alexandru Barna, et al.
BMC Proceedings|January 17, 2024
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityMaximilian J Hochmair, Mojca Unk, Jelena Spasic, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Clinical Lung Cancer|August 9, 2014
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerJean-Louis Pujol, Luis Paz-Ares, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE TrialMartin Reck, Mark A Socinski, Alexander Luft, et al.
Pageof 3